Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1

L. I. Yue Hua, Jie Fan, Charles H. Lang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The purpose of the present study was to determine whether endogenous elevations in glucocorticoids mediate the changes in insulin-like growth factor (IGF) I and IGF binding protein (IGFBP) 1 levels in plasma and tissues observed after in vivo administration of lipopolysaccharide (LPS). In overnightfasted male rats LPS injected via the tail vein decreased the IGF-I concentration in plasma, liver, and skeletal muscle (30-45%) and increased IGF-I content in kidney (∼3-fold). LPS also decreased IGF-I mRNA abundance in liver and muscle and increased gene expression in kidney. Concomitantly, IGFBP-1 levels in plasma, liver, and muscle were markedly elevated by LPS. All these changes were associated with a greater than fourfold elevation in plasma corticosterone. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 completely prevented or blunted the LPS-induced changes in IGF-I content in plasma, liver, muscle, and kidney. In liver and muscle RU-486 significantly attenuated the reduction in IGF-I mRNA abundance produced by LPS, but in kidney the LPS-induced increase in IGF-I mRNA was still evident. In contrast, pretreatment with RU-486 did not prevent or attenuate the LPS-induced increase in IGFBP-1 levels in plasma, liver, or muscle. These data suggest that glucocorticoids play a major role in regulating IGF-I mRNA and peptide content in tissues in response to LPS, but the increased IGFBP-1 in blood and tissues induced by LPS appears largely glucocorticoid independent.

Original languageEnglish (US)
Pages (from-to)R1998-R2003
JournalAmerican Journal of Physiology
Volume272
Issue number6 PART 2
StatePublished - Dec 1 1997

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Endotoxins
Glucocorticoids
Lipopolysaccharides
Mifepristone
Liver
Muscles
Kidney
Messenger RNA
Glucocorticoid Receptors
Corticosterone
Tail
Veins
Skeletal Muscle

All Science Journal Classification (ASJC) codes

  • Physiology (medical)

Cite this

@article{71b75bf1afe340ccb2e142ff68f0fe3f,
title = "Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1",
abstract = "The purpose of the present study was to determine whether endogenous elevations in glucocorticoids mediate the changes in insulin-like growth factor (IGF) I and IGF binding protein (IGFBP) 1 levels in plasma and tissues observed after in vivo administration of lipopolysaccharide (LPS). In overnightfasted male rats LPS injected via the tail vein decreased the IGF-I concentration in plasma, liver, and skeletal muscle (30-45{\%}) and increased IGF-I content in kidney (∼3-fold). LPS also decreased IGF-I mRNA abundance in liver and muscle and increased gene expression in kidney. Concomitantly, IGFBP-1 levels in plasma, liver, and muscle were markedly elevated by LPS. All these changes were associated with a greater than fourfold elevation in plasma corticosterone. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 completely prevented or blunted the LPS-induced changes in IGF-I content in plasma, liver, muscle, and kidney. In liver and muscle RU-486 significantly attenuated the reduction in IGF-I mRNA abundance produced by LPS, but in kidney the LPS-induced increase in IGF-I mRNA was still evident. In contrast, pretreatment with RU-486 did not prevent or attenuate the LPS-induced increase in IGFBP-1 levels in plasma, liver, or muscle. These data suggest that glucocorticoids play a major role in regulating IGF-I mRNA and peptide content in tissues in response to LPS, but the increased IGFBP-1 in blood and tissues induced by LPS appears largely glucocorticoid independent.",
author = "{Yue Hua}, {L. I.} and Jie Fan and Lang, {Charles H.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "272",
pages = "R1998--R2003",
journal = "American Journal of Physiology",
issn = "0002-9513",
publisher = "American Physiological Society",
number = "6 PART 2",

}

Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1. / Yue Hua, L. I.; Fan, Jie; Lang, Charles H.

In: American Journal of Physiology, Vol. 272, No. 6 PART 2, 01.12.1997, p. R1998-R2003.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1

AU - Yue Hua, L. I.

AU - Fan, Jie

AU - Lang, Charles H.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - The purpose of the present study was to determine whether endogenous elevations in glucocorticoids mediate the changes in insulin-like growth factor (IGF) I and IGF binding protein (IGFBP) 1 levels in plasma and tissues observed after in vivo administration of lipopolysaccharide (LPS). In overnightfasted male rats LPS injected via the tail vein decreased the IGF-I concentration in plasma, liver, and skeletal muscle (30-45%) and increased IGF-I content in kidney (∼3-fold). LPS also decreased IGF-I mRNA abundance in liver and muscle and increased gene expression in kidney. Concomitantly, IGFBP-1 levels in plasma, liver, and muscle were markedly elevated by LPS. All these changes were associated with a greater than fourfold elevation in plasma corticosterone. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 completely prevented or blunted the LPS-induced changes in IGF-I content in plasma, liver, muscle, and kidney. In liver and muscle RU-486 significantly attenuated the reduction in IGF-I mRNA abundance produced by LPS, but in kidney the LPS-induced increase in IGF-I mRNA was still evident. In contrast, pretreatment with RU-486 did not prevent or attenuate the LPS-induced increase in IGFBP-1 levels in plasma, liver, or muscle. These data suggest that glucocorticoids play a major role in regulating IGF-I mRNA and peptide content in tissues in response to LPS, but the increased IGFBP-1 in blood and tissues induced by LPS appears largely glucocorticoid independent.

AB - The purpose of the present study was to determine whether endogenous elevations in glucocorticoids mediate the changes in insulin-like growth factor (IGF) I and IGF binding protein (IGFBP) 1 levels in plasma and tissues observed after in vivo administration of lipopolysaccharide (LPS). In overnightfasted male rats LPS injected via the tail vein decreased the IGF-I concentration in plasma, liver, and skeletal muscle (30-45%) and increased IGF-I content in kidney (∼3-fold). LPS also decreased IGF-I mRNA abundance in liver and muscle and increased gene expression in kidney. Concomitantly, IGFBP-1 levels in plasma, liver, and muscle were markedly elevated by LPS. All these changes were associated with a greater than fourfold elevation in plasma corticosterone. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 completely prevented or blunted the LPS-induced changes in IGF-I content in plasma, liver, muscle, and kidney. In liver and muscle RU-486 significantly attenuated the reduction in IGF-I mRNA abundance produced by LPS, but in kidney the LPS-induced increase in IGF-I mRNA was still evident. In contrast, pretreatment with RU-486 did not prevent or attenuate the LPS-induced increase in IGFBP-1 levels in plasma, liver, or muscle. These data suggest that glucocorticoids play a major role in regulating IGF-I mRNA and peptide content in tissues in response to LPS, but the increased IGFBP-1 in blood and tissues induced by LPS appears largely glucocorticoid independent.

UR - http://www.scopus.com/inward/record.url?scp=33745368882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745368882&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33745368882

VL - 272

SP - R1998-R2003

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0002-9513

IS - 6 PART 2

ER -